Lilly, Takeda Pharmaceuticals to Appeal $9 Billion Punitive Damages Award

A jury in Louisiana also awarded $1.475 million in compensatory damages. This is the first federal case to be tried and the first in the consolidated multidistrict litigation involving Actos, a diabetes drug the companies co-promoted from 1999 to 2006.

Eli Lilly and Company and Takeda Pharmaceuticals U.S.A., Inc. announced they will challenge a jury's awards of $9 billion in punitive damages and $1.475 million in compensatory damages in Terrence Allen, et al. v. Takeda Pharmaceuticals North America, Inc., et al., No. 6:12-cv-00064, in U.S. District Court for the Western District of Louisiana. The jury allocated 75 percent of the liability to Takeda and 25 percent to Lilly and awarded $6 billion in punitive damages from Takeda and $3 billion from Lilly in the case, which involved a claim that Takeda Pharmaceuticals concealed cancer risks associated with its diabetes drug Actos.

Both companies issued statements stating that all three previous Actos trials resulted in judgments for Takeda Pharmaceuticals. This huge punitives award came in a trial that began Feb. 3 in the Lafayette, La., courtroom of U.S. District Judge Rebecca Doherty.

"While we have empathy for the plaintiff, we believe the evidence did not support his claims. Lilly disagrees with the verdict and we intend to vigorously challenge this outcome through all available legal means," Mike Harrington, Lilly’s senior vice president and general counsel, said in an April 8 statement posted by the company.

"Takeda respectfully disagrees with the verdict and we intend to vigorously challenge this outcome through all available legal means, including possible post-trial motions and an appeal," Kenneth D. Greisman, senior vice president and general counsel of Deerfield, Ill.-based Takeda Pharmaceuticals U.S.A., Inc., said in its statement. "We have empathy for the Allens, but we believe the evidence did not support a finding that ACTOS caused his bladder cancer. We also believe we demonstrated that Takeda acted responsibly with regard to ACTOS."

According to Lilly's statement, its agreement with Takeda Pharmaceuticals stipulates that Lilly will be indemnified by Takeda for its losses and expenses with respect to the U.S. litigation and other related expenses in accordance with the terms of its indemnification agreement. It says the two companies co-promoted Actos from 1999 to 2006.

Download Center

  • Safety Metrics Guide

    Is your company leveraging its safety data and analytics to maintain a safe workplace? With so much data available, where do you start? This downloadable guide will give you insight on helpful key performance indicators (KPIs) you should track for your safety program.

  • Job Hazard Analysis Guide

    This guide includes details on how to conduct a thorough Job Hazard Analysis, and it's based directly on an OSHA publication for conducting JHAs. Learn how to identify potential hazards associated with each task of a job and set controls to mitigate hazard risks.

  • A Guide to Practicing “New Safety”

    Learn from safety professionals from around the world as they share their perspectives on various “new views” of safety, including Safety Differently, Safety-II, No Safety, Human and Organizational Performance (HOP), Resilience Engineering, and more in this helpful guide.

  • Lone Worker Safety Guide

    As organizations digitalize and remote operations become more commonplace, the number of lone workers is on the rise. These employees are at increased risk for unaddressed workplace accidents or emergencies. This guide was created to help employers better understand common lone worker risks and solutions for lone worker risk mitigation and incident prevention.

  • EHS Software Buyer's Guide

    Learn the keys to staying organized, staying sharp, and staying one step ahead on all things safety. This buyer’s guide is designed for you to use in your search for the safety management solution that best suits your company’s needs.

  • Vector Solutions

OH&S Digital Edition

  • OHS Magazine Digital Edition - June 2022

    June 2022

    Featuring:

    • SAFETY CULTURE
      Corporate Safety Culture Is Workplace Culture
    • HEAT STRESS
      Keeping Workers Safe from Heat-Related Illnesses & Injuries
    • EMPLOYEE HEALTH SCREENING
      Should Employers Consider Oral Fluid Drug Testing?
    • PPE FOR WOMEN
      Addressing Physical Differences
    View This Issue